Blood
Articles in this Issue
Reduced post-transplant alpha-diversity and domination by enterococcus faecium are associated with increased mortality in pediatric recipients of allogeneic hematopoietic cell transplantation.
Abstract Background: In adult cohorts, gut microbiome features during allogeneic hematopoietic transplant (allo-HCT) period are associated w...
AMPK agonism improves In vivo CAR T cell function across a range of platforms and clinical indications
Abstract The metabolic profile of adoptive cell therapies profoundly impacts their subsequent in vivo persistence and function. In these stu...
DNA methylation profiling identifies two epigenetic subgroups with prognostic implications in pediatric acute promyelocytic leukemia: The JCCG study, JPLSG AML-P05
Abstract Introduction: Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML) characterized by the t(15;17)/P...
Long-term therapy with eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria: Two-year interim results of a prospective multicenter observational study
Abstract Introduction: The complement C5-inhibition with eculizumab or ravulizumab is a current standard of care in patients with paroxysmal...
AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)
Abstract Therapy with JAK2 inhibitors (JAK2i) is a standard of care for myelofibrosis (MF). All FDA-approved JAK2i are type-I inhibitors, an...
T cell-derived TNF-α mediates myelofibrosis via JAK2/STAT3-ADAM17 axis in JAK2V617F⁺ myeloproliferative neoplasms
Abstract Background: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by excessive myeloid pro...
iPSC-derived, multiplex-engineered CD8αβT cells deliver antigen-specific, potent, and durable tumor cytotoxicity without CD4αβT support – powering scalable, off-the-shelf allogeneic αβT cell therapy in hematological malignancies
Abstract Autologous T cell therapies have reshaped cancer treatment paradigms, yet persistent challenges in scalability, product consistency...
Comparison of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in Acute Myeloid Leukemia: Single-center randomized controlled trial from India
Abstract INTRODUCTION The treatment strategy of patients with Acute myeloid leukaemia (AML) includes induction chemotherapy which is to achi...
Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial
Abstract Background: Graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (...
High response rates and early treatment patterns with venetoclax and azacitidine from the prospective liven study: Real-world AML care in Canada
Abstract Introduction: Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. The combination of venetoclax and a...
Proteogenomic analysis of NPM1-mutated AML reveals clinical heterogeneity related to differentiation states and mitochondrial metabolism
Abstract Introduction: Acute myeloid leukemia (AML) is a clonal malignancy characterized by specific genetic alterations that impact cell di...
Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1
Abstract Introduction: Induction chemotherapy for pediatric AML has historically used cytarabine, daunorubicin and etoposide (ADE). However,...
Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL
Abstract Introduction The importance of safer and more convenient effective therapy is paramount in indolent B-cell non-Hodgkin lymphoma (iN...
Xgboost model using diagnostic CBC to predict early mortality in newly diagnosed AML patients
Abstract Background: Even among clinically fit patients, early mortality after intensive induction chemotherapy remains a challenge in newly...
Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study
Abstract VEN/AZA is the standard frontline treatment for adults with ND AML (including FLT3mut+ disease) ineligible for intensive induction...
Exposure to epcoritamab is associated with improved T-cell functionality and dynamic changes in CD8+ T-cells in diffuse large B-cell lymphoma: Insights from epcore NHL-6
Abstract INTRODUCTION: Epcoritamab (epcor) is a subcutaneously (SC) administered bispecific T-cell engager (CD3-BsAb TCE) approved for the tr...
Cell-free CAR therapy: BCMA-CAR-T cell-derived exosomes exhibit potent anti-myeloma activity
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has shown remarkable clinical efficacy in patients with...
Decisions about gene therapy do not occur in isolation: Co-development of a website about treatment options for sickle cell disease
Abstract Background: Gene therapy (GT) and hematopoietic stem cell transplantation (HSCT) are two potentially transforma...
Divergent immune programs in EBV⁺ PCNSL: A multiomic study of AR-PCNSL and cns-PTLD
Abstract Background Primary CNS lymphoma (PCNSL) is a rare, aggressive diffuse large B-cell lymphoma confined to the CNS, with poor outcomes...
The effects of bruton tyrosine kinase inhibitors on the waldenstrom macroglobulinemia microenvironment
Abstract Waldenstrom Macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma driven primarily by the activating mutation MYD88 (L265P) a...
Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
Abstract Background: HRQoL is often impaired in pts with R/R LBCL (Abramson et al. ASH 2021). SUNMO (NCT05171647), a randomized Phase III st...
Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study
Abstract Background: Post-transplant lymphoproliferative disorders (PTLDs) are rare lymphomas that arise as complications of solid organ tra...
Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations
Abstract Background: Individuals with sickle cell disease (SCD) face an elevated risk of myeloid leukemias. Recently, myelodysplastic syndro...
Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study
Abstract Background: Natural killer/T cell lymphoma (NKTCL) is a distinct subtype of non-Hodgkin lymphoma, with a higher incidence in East As...
Gut permeability marker zonulin in sickle cell disease: Preliminary associations with vaso-occlusive crisis frequency
Abstract Background: Vaso-occlusive crises (VOC) are a hallmark complication of sickle cell disease (SCD), driven by neutrophil activation a...